Cyclodextrin Treatment for Sickle Cell RBC Deformability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for safe and effective treatments for sickle cell disease that improve red blood cell deformability without increasing susceptibility to hemolysis, as current treatments like gene therapy carry risks and existing therapies primarily manage symptoms or complications.
Innovation Solution
Administration of hydroxypropyl-beta-cyclodextrin (HPBCD) to reduce membrane cholesterol concentration, enhance deformability, and decrease hemolysis of red blood cells in subjects with or at risk for sickle cell disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (gene therapy, hydroxyurea, voxelotor) are administered to treat sickle cell disease, then symptoms and complications are managed or hemoglobin function is improved, but the treatments carry risks (cancer induction) or do not address the underlying membrane cholesterol issue
Solution Approach 1:
The patent extracts and removes the harmful element (excess cholesterol) from the red blood cell membrane using cyclodextrin. This extraction approach directly addresses the root cause of sickle cell pathology without introducing the cancer risk associated with gene therapy, thereby improving treatment safety while eliminating harmful factors.
Solution Approach 2:
Cyclodextrin serves as an intermediary substance that facilitates the removal of cholesterol from red blood cell membranes. This mediator approach provides a safe mechanism to improve RBC deformability and reduce sickling without the direct genetic manipulation risks, resolving the contradiction between effective treatment and cancer risk.
2Ease of operation
If red blood cell deformability is improved to prevent vaso-occlusive crises, then blood flow is enhanced, but current methods may increase susceptibility to hemolysis
Solution Approach 1:
The patent changes the physical-chemical parameter of membrane cholesterol concentration to optimize RBC properties. By reducing cholesterol to optimal levels (not complete removal), the method improves deformability while maintaining membrane integrity and preventing hemolysis, thus resolving the contradiction between ease of operation and reliability.
3Shape
If membrane cholesterol concentration is reduced to improve RBC deformability, then blood flow through vessels is enhanced, but excessive cholesterol removal may compromise membrane integrity
Solution Approach 1:
The patent employs feedback control where cyclodextrin treatment is monitored and adjusted to achieve optimal cholesterol levels. This feedback mechanism ensures that cholesterol removal stops at the point where deformability is maximized without compromising membrane integrity, resolving the contradiction between shape improvement and strength maintenance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
HPBCD effectively reduces membrane cholesterol levels, increases red blood cell deformability, and decreases hemolysis, potentially improving clinical outcomes for sickle cell disease patients.
Implementation Method 1
Administration of hydroxypropyl-beta-cyclodextrin (HPBCD) to reduce membrane cholesterol concentration
Data Source
AI summary
The present disclosure provides methods and compositions for treating or preventing a sickle cell disease (SCD). The SCD may include sickle cell anemia (SCA). The method may include administering a composition such as a cyclodextrin to a subject in need of SCD treatment. Some embodiments include contacting a RBC with a cyclodextrin.